Viaderma Stock Fundamentals
| VDRM Stock | USD 0.01 0.0004 4.44% |
Viaderma fundamentals help investors to digest information that contributes to Viaderma's financial success or failures. It also enables traders to predict the movement of Viaderma Pink Sheet. The fundamental analysis module provides a way to measure Viaderma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viaderma pink sheet.
Viaderma |
Viaderma Company Return On Asset Analysis
Viaderma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Viaderma Return On Asset | -0.91 |
Most of Viaderma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viaderma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Viaderma has a Return On Asset of -0.9123. This is 89.57% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.
Viaderma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Viaderma's current stock value. Our valuation model uses many indicators to compare Viaderma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viaderma competition to find correlations between indicators driving Viaderma's intrinsic value. More Info.Viaderma is rated first in return on asset category among its peers. It is rated first in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viaderma's earnings, one of the primary drivers of an investment's value.Viaderma Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viaderma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Viaderma could also be used in its relative valuation, which is a method of valuing Viaderma by comparing valuation metrics of similar companies.Viaderma is currently under evaluation in return on asset category among its peers.
Viaderma Fundamentals
| Return On Asset | -0.91 | |||
| Operating Margin | (13.28) % | |||
| Current Valuation | 6.18 M | |||
| Shares Outstanding | 137.32 K | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 2.01 X | |||
| Revenue | 44.69 K | |||
| Gross Profit | 37.63 K | |||
| EBITDA | (592.43 K) | |||
| Net Income | (1.52 M) | |||
| Cash And Equivalents | 13.08 K | |||
| Debt To Equity | 20.90 % | |||
| Current Ratio | 0.29 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (167.36 K) | |||
| Earnings Per Share | 0.16 X | |||
| Beta | -0.42 | |||
| Market Capitalization | 82.27 K | |||
| Total Asset | 426.56 K | |||
| Retained Earnings | (7.38 M) | |||
| Working Capital | (445 K) | |||
| Current Asset | 185 K | |||
| Current Liabilities | 630 K | |||
| Z Score | -28.3 | |||
| Net Asset | 426.56 K |
About Viaderma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viaderma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viaderma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viaderma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California. Viaderma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.